

## Malaria Consortium US Annual Report 2019-2020 (FY20)

[Malaria Consortium US](#) is a 501(c)(3) tax-exempt Charity (EIN 98-0627052) and the US entity of Malaria Consortium. Malaria Consortium is a global leader dedicated to bringing an end to deaths from malaria and other treatable and preventable diseases in Africa and Asia. We liaise with corporations, foundations, individuals, and organizations in the U.S. to ensure all philanthropic donations make a positive impact for those most in need.

Malaria Consortium US is governed by a Board of Directors, who have met twice during this reporting period to oversee the allocation of grant funds. We select grant options based on identified need and prioritized technical recommendations made by the Global Technical Director of Malaria Consortium. You will see that costs in the U.S. are kept to a minimum to maximize the impact of our activities.

In this period, we have seen significant growth in funding and the opportunity to support a number of key initiatives. The majority [about 60%] of our received funding has been restricted and dedicated to our highly impactful Seasonal Malaria Chemoprevention (SMC) activities in the Sahel region of Africa. This program reaches eligible children under the age of five, with preventive antimalarial treatments, once a month, during a 4-month rainy season, when, alongside increased rainfall there is an increase in mosquito population and in malaria transmission. We were able to reach five hundred thousand more children in Burkina Faso in 2019 compared to 2018 as a result of these dedicated funds. Total revenue for FY20 was US\$ 1,689,485, with a total expenditure of US\$ 620,585. It should be noted that the giving season, when the majority of our income is received, comes after the time of year when spending can be done on SMC (July to November). Grants towards SMC, therefore, will fall in the financial year after the funding is received and this financial year's SMC grant level was based on giving in the FY19.

We know that we cannot eliminate malaria, nor the comorbidities we find in malaria-affected communities, with one tool alone. The balance of our funding is used to support both service delivery and operational research. In this reporting period we were able to make three additional grants. The first grant supported mobile malaria workers in Northern Cambodia to track down and treat cases of *falciparum* malaria in workers in the forests, where the remains of the parasite pool is found, together with a growing risk of resistance to treatment. The second grant supported community health workers in Mozambique with digital tools to support remote communities, who cannot easily access health facilities, with key primary health interventions and recording of diagnosis and treatment for malaria, pneumonia, and diarrhea and of referrals where treatment cannot be given. The third grant supported community health activity for children under five, working alongside UNICEF, in Unity State of South Sudan.

The Board of Malaria Consortium US wishes to thank all those who have supported our mission and work around the world.

Dr. John Horton (Chair)


Signature:



Date: June 20, 2020

Charles Nelson (President)

Signature:



Date: June 20, 2020